TOP2A modulates signaling via the AKT/mTOR pathway to promote ovarian cancer cell proliferation
Ovarian cancer (OC) is a form of gynecological malignancy that is associated with worse patient outcomes than any other cancer of the female reproductive tract. Topoisomerase II α (TOP2A) is commonly regarded as an oncogene that is associated with malignant disease progression in a variety of cancers, its mechanistic functions in OC have yet to be firmly established. We explored the role of TOP2A in OC through online databases, clinical samples, in vitro and in vivo experiments. And initial analyses of public databases revealed high OC-related TOP2A expression in patient samples that was related to poorer prognosis. This was confirmed by clinical samples in which TOP2A expression was elevated in OC relative to healthy tissue. Kaplan-Meier analyses further suggested that higher TOP2A expression levels were correlated with worse prognosis in OC patients. In vitro, TOP2A knockdown resulted in the inhibition of OC cell proliferation, with cells entering G1 phase arrest and undergoing consequent apoptotic death. In rescue assays, TOP2A was confirmed to regulate cell proliferation and cell cycle through AKT/mTOR pathway activity. Mouse model experiments further affirmed the key role that TOP2A plays as a driver of OC cell proliferation. These data provide strong evidence supporting TOP2A as an oncogenic mediator and prognostic biomarker related to OC progression and poor outcomes. At the mechanistic level, TOP2A can control tumor cell growth via AKT/mTOR pathway modulation. These preliminary results provide a foundation for future research seeking to explore the utility of TOP2A inhibitor-based combination treatment regimens in platinum-resistant recurrent OC patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
Cancer biology & therapy - 25(2024), 1 vom: 31. März, Seite 2325126 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhang, Kaiwen [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 07.03.2024 Date Revised 15.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/15384047.2024.2325126 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36935446X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36935446X | ||
| 003 | DE-627 | ||
| 005 | 20240315233523.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240306s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/15384047.2024.2325126 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1330.xml |
| 035 | |a (DE-627)NLM36935446X | ||
| 035 | |a (NLM)38445610 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zhang, Kaiwen |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a TOP2A modulates signaling via the AKT/mTOR pathway to promote ovarian cancer cell proliferation |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.03.2024 | ||
| 500 | |a Date Revised 15.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Ovarian cancer (OC) is a form of gynecological malignancy that is associated with worse patient outcomes than any other cancer of the female reproductive tract. Topoisomerase II α (TOP2A) is commonly regarded as an oncogene that is associated with malignant disease progression in a variety of cancers, its mechanistic functions in OC have yet to be firmly established. We explored the role of TOP2A in OC through online databases, clinical samples, in vitro and in vivo experiments. And initial analyses of public databases revealed high OC-related TOP2A expression in patient samples that was related to poorer prognosis. This was confirmed by clinical samples in which TOP2A expression was elevated in OC relative to healthy tissue. Kaplan-Meier analyses further suggested that higher TOP2A expression levels were correlated with worse prognosis in OC patients. In vitro, TOP2A knockdown resulted in the inhibition of OC cell proliferation, with cells entering G1 phase arrest and undergoing consequent apoptotic death. In rescue assays, TOP2A was confirmed to regulate cell proliferation and cell cycle through AKT/mTOR pathway activity. Mouse model experiments further affirmed the key role that TOP2A plays as a driver of OC cell proliferation. These data provide strong evidence supporting TOP2A as an oncogenic mediator and prognostic biomarker related to OC progression and poor outcomes. At the mechanistic level, TOP2A can control tumor cell growth via AKT/mTOR pathway modulation. These preliminary results provide a foundation for future research seeking to explore the utility of TOP2A inhibitor-based combination treatment regimens in platinum-resistant recurrent OC patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a AKT/mTOR signaling pathway | |
| 650 | 4 | |a Ovarian cancer | |
| 650 | 4 | |a TOP2A | |
| 650 | 4 | |a prognosis | |
| 650 | 4 | |a proliferation | |
| 650 | 4 | |a rescue experiments | |
| 650 | 7 | |a DNA Topoisomerases, Type II |2 NLM | |
| 650 | 7 | |a EC 5.99.1.3 |2 NLM | |
| 650 | 7 | |a Proto-Oncogene Proteins c-akt |2 NLM | |
| 650 | 7 | |a EC 2.7.11.1 |2 NLM | |
| 650 | 7 | |a TOR Serine-Threonine Kinases |2 NLM | |
| 650 | 7 | |a EC 2.7.11.1 |2 NLM | |
| 650 | 7 | |a TOP2A protein, human |2 NLM | |
| 650 | 7 | |a EC 5.99.1.3 |2 NLM | |
| 650 | 7 | |a Top2a protein, mouse |2 NLM | |
| 650 | 7 | |a EC 5.99.1.3 |2 NLM | |
| 700 | 1 | |a Zheng, Xingyu |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Yiqing |e verfasserin |4 aut | |
| 700 | 1 | |a Feng, Xinyu |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Xirong |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Wenlu |e verfasserin |4 aut | |
| 700 | 1 | |a Gao, Chao |e verfasserin |4 aut | |
| 700 | 1 | |a Yan, Ye |e verfasserin |4 aut | |
| 700 | 1 | |a Tian, Wenyan |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Yingmei |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer biology & therapy |d 2002 |g 25(2024), 1 vom: 31. März, Seite 2325126 |w (DE-627)NLM12031438X |x 1555-8576 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2024 |g number:1 |g day:31 |g month:03 |g pages:2325126 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/15384047.2024.2325126 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2024 |e 1 |b 31 |c 03 |h 2325126 | ||